Analysts Set CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Target Price at $8.36

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been given an average rating of “Moderate Buy” by the nine research firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $8.3571.

Several equities research analysts have commented on CAMP shares. Weiss Ratings lowered shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Zacks Research downgraded CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Leerink Partners increased their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 10th. Finally, Rodman & Renshaw assumed coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They set a “buy” rating and a $7.00 target price on the stock.

Hedge Funds Weigh In On CAMP4 Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. EcoR1 Capital LLC acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth approximately $1,992,000. Bridgeway Capital Management LLC acquired a new position in shares of CAMP4 Therapeutics during the second quarter valued at approximately $36,000. Jefferies Financial Group Inc. bought a new stake in CAMP4 Therapeutics during the fourth quarter worth approximately $70,000. China Universal Asset Management Co. Ltd. bought a new stake in CAMP4 Therapeutics during the fourth quarter worth approximately $61,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in CAMP4 Therapeutics in the fourth quarter worth approximately $115,000.

CAMP4 Therapeutics Stock Performance

Shares of CAMP opened at $3.71 on Friday. The firm has a fifty day moving average of $4.26 and a 200-day moving average of $4.55. The company has a market cap of $192.66 million, a price-to-earnings ratio of -1.57 and a beta of 0.10. CAMP4 Therapeutics has a 1 year low of $1.32 and a 1 year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). The firm had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. Analysts predict that CAMP4 Therapeutics will post -0.84 EPS for the current year.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.